Bonti Announces Topline Results of EB-001 Phase 2A Clinical Study in Glabellar Lines

Bonti, a privately-held, clinical-stage biotechnology company, today announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar (frown) lines. The study achieved its objectives and confirmed both favorable safety and the expected clinical efficacy profile. EB-001 is a novel serotype E botulinumneurotoxin with a unique efficacy profile, characterized by fast … Read more

Bam, biff, kerpow, krunch!!

Could it be?  An end to S. Mutans? Image via Wikipedia UCLA clinical study leads to “smartbomb” mouthwash that destroys S. mutans In a recent clinical study, 12 subjects who rinsed just one time with the experimental mouthwash experienced a nearly complete elimination of the S. mutans bacteria over the entire four-day testing period. The … Read more